Introduction
T he most common primary tumors of the brain are malignant gliomas, and they are exemplified by invasive growth and resistance to therapy. Routine Electronic supplementary material The online version of this article (doi:10.1007/s11307-014-0743-2) contains supplementary material, which is available to authorized users. methods to diagnose, grade, and classify gliomas include pathology of biopsy or surgically resected specimens, and these methods frequently are limited by sampling errors [1, 2] . Consequently, clinical decisions are frequently supported by non-invasive imaging [3] . Though ubiquitously employed clinically, X-ray computed tomography (CT) and magnetic resonance imaging (MRI) tend to poorly discriminate disease margins and provide no molecular information attributable to the pathology of glioma, particularly where tumors are highly infiltrative. Stemming from the sensitivity and the ability to discriminate tissues based upon certain molecular characteristics, positron emission tomography (PET) imaging has the potential to overcome many of the limitations associated with conventional brain tumor imaging methods. However, PET imaging tracers available for routine use in brain tumor studies are limited. For example, PET with 2-deoxy-2-[
18 F]fluoro-D-glucose ([ 18 F]FDG), which is used widely for grading brain tumors [4] , tends to suffer from modest to poor tumor-tobackground ratios due to significant accumulation of [ 18 F]FDG in normal brain. Thus, improved molecular imaging biomarkers suitable for detection and characterization of gliomas could positively impact patient care.
Translocator protein (TSPO), formerly referred to as peripheral benzodiazepine receptor (PBR), is an 18-kDa protein primarily localized in mitochondria. TSPO plays numerous roles in key biological processes in healthy tissue and diseases, which include the metabolism of cholesterol, biosynthesis of steroids biosynthesis, proliferation, and apoptosis [5, 6] . Accordingly, TSPO expression is elevated in several clinically important disease states, including Alzheimer's disease [7, 8] , Huntington's disease [9] , Parkinson's disease [10] , and cancer. In cancer, TSPO expression is reportedly associated with advanced disease and diminished survival [11] [12] [13] . We have explored TSPO as a molecular imaging target in colon cancer [14] , breast cancer [15] , and glioma [16] [17] [18] , as TSPO PET could potentially serve as a useful cancer imaging biomarker [6] .
In pursuit of improved TSPO ligands for cancer imaging, we reported the synthesis and structure-activity relationship (SAR) analysis of a library of novel pyrazolopyrimidines [18] . In that study, we identified a novel ligand, (2-(5,7-diethyl-2-(4-(2-fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide, VUIIS1008), that exhibited a 36-fold enhancement in binding affinity (K i = 0.3 nM) compared to the previously reported parent compound, DPA-714 (K i =10.9 nM) [16, 18] (Fig. 1) . Radiolabeling this compound with fluorine-18 ( 18 F) resulted in [ 18 F]VUIIS1008, which exhibited promising preliminary characteristics for cancer imaging in preliminary studies [18] . The purpose of the present study was to explore the in vivo imaging characteristics of the new ligand quantitatively in healthy mice and a rat model of glioma. Quantitative imaging data obtained in a preclinical glioma model using [ 18 F]VUIIS1008 were compared to an analogous study using a structurally similar pyrazolopyrimidine, [
18 F]DPA-714, which has been advanced as a PET agent for neuroinflammation [19] and oncology [6, 16, 20] .
Materials and Methods

Chemistry and Radiochemistry
PBR06 was prepared as previously described [17] . [ 18 F]VUIIS1008, the requisite tosylate ester precursor, and nonradioactive VUIIS1008 were prepared as previously described [18] . Specific activities of the [
18 F]VUIIS1008 produced in this study were 4,600±2,160 Ci/mmol (170±80 TBq/mmol) (mean± SD) (n=10).
Animals
Studies involving animals were conducted in accordance with institutional and federal guidelines. Prior to imaging, all animals were allowed food and water ad libitum. Healthy, 10-week-old C57BL/6 mice (~25 g; The Jackson Laboratory, Bar Harbor, Maine, USA) were used for tracer biodistribution studies. Healthy, 10-week-old male Wistar rats (~300 g; Harlan Laboratories, Indianapolis, IN, USA) were inoculated with 1.0×10 5 C6 glioma cells (ATTC, Manassas, VA, USA) in the right brain hemisphere 2 weeks prior to imaging studies as described [16] [17] [18] 21] . Rats were surgically affixed with venous and arterial catheters prior to imaging.
MRI
For anatomical registration with PET, MRI was performed by securing the rat in a radiofrequency coil (38-mm inner diameter) and then placing this in a 4.7-T horizontal bore MRI system (Varian Inc., Palo Alto, CA, USA). Body temperature was maintained at 37°C using heated airflow. To properly position the subsequent scans, an initial MRI multi-slice gradient-echo sequence (repetition time, 150 ms; echo time, 3.5 ms; matrix, 128× 128; field of view, 40×40 mm 2 ; slice thickness, 2 mm) was used to acquire seven slices in each imaging plane (axial, coronal, sagittal). A multi-slice, T 2 -weighted fast spin-echo scan (8 echoes and 8.0-ms echo spacing; effective echo time, 32 ms) was then collected (repetition time of 2,000 ms; field of view of 32×32 mm 2 ; matrix of 128×128; 16 acquisitions; and 8 coronal slices of 2-mm thickness). All rat PET/CT studies were performed after the MRI scan in less than 24 h.
PET/CT Acquisition and Reconstruction
For imaging studies, the tracer was administered intravenously (bolus) with initiation of a dynamic PET scan, either via retroorbital injection (mice; 0.25 mCi, 9.25 MBq) or jugular catheter (rats; 1.2±0.2 mCi, 44.9±8.56 MBq) while in a microPET Focus 220 scanner (Siemens, Knoxville, TN, USA). For displacement studies, non-radioactive TSPO ligand challengers (VUIIS1008 or PBR06; 10 mg/kg) were administered via retro-orbital injection 30 min after tracer infusion. For blocking studies, VUIIS1008 (10 mg/kg) was administered intravenously 5 min prior to [ 18 F]VUIIS1008. PET data were collected in list-mode format for 60 or 90 min, followed by another CT (microCAT II; Siemens) scan for further attenuation correction (rats only). The dynamic PET acquisitions were analyzed by dividing into 12 10-s frames for the first 2 min and 300-s frames for the remainder of the 60-or 90-min dynamic scans. Three-dimensional sonograms were obtained by binning the raw data within each frame using a span of three and ring difference of 47. The tomographic images (128×128×95) were then obtained by reconstructing sinograms with voxel sizes of 0.095×0.095×0.08 cm 3 after scatter and attenuation corrections. The algorithm used in this reconstruction was a two-dimensional ordered-subsets expectation-maximization algorithm (16 subsets and four iterations). Attenuation correction (rats only) was performed by segmenting and projecting an attenuation map from the CT images with a span of 47 and ring difference of 23.
Thin-Layer Chromatography for Radiometabolite Analysis
Plasma radiometabolites of [ 18 F]VUIIS1008 were evaluated by thin-layer chromatography (TLC). Rat arterial blood (200 μl) was collected at 2, 12, 30, 60, and 90 min following administration of 1.2±0.2 mCi (44.9±8.56 MBq) of [ 18 F]VUIIS1008 in rats (n=4). Plasma (145 μl) was denatured with a mixture of acetonitrile/water (340 μl, 7/1, v/v), centrifuged, and the supernatant spotted on silica/ glass TLC plates (Waterman, GE Healthcare, Little Chalfont, UK). TLC plates were developed in a solution of 10 % methanol in dichloromethane and scanned using an AR-2000 radio-TLC imaging scanner (Bioscan/TriFoil, Washington, DC, USA). TLC plates were evaluated by determining the ratio of the parent radioligand ([ 18 F]VUIIS1008) with respect to the total radioactivity in the plasma.
PET Imaging Analysis
Three-dimensional regions of interest (ROIs) were manually drawn around the heart, lung, kidney, and liver in mouse images using ASIPro (Siemens). Time-activity curves (TACs) were generated over these regions for the duration of the scan. For glioma-bearing rats, TACs were generated by manually drawing three-dimensional ROIs around the tumor and contralateral normal brain using ASIPro. Tumor ROIs included areas of central necrosis if present. The arterial input function (AIF) was manually computed from plasma sampling (15 μl) that occurred concomitantly with imaging. Using TLC data, a metabolite-corrected plasma TAC was used as the input function. In this study, one-tissue and two-tissue models were evaluated using the PMOD software package (version 2.6) as published [16] . Total distribution volume (V T ) and binding potential (BP ND ; k 3 /k 4 ) were estimated using the kinetic parameters of K 1 , k 2 , k 3 , and k 4 for various tissues [22] .
Histology
For histology, rat brains were harvested and fixed in 4 % buffered formalin for 48 h, followed by paraffin embedding. The paraffin sections (5.0 μm) were dewaxed in xylene, rehydrated with several ethanol washes, and placed in distilled water for histology and immunohistochemistry (IHC). Tissue sections (5.0 μm) were stained with TSPO-specific rabbit polyclonal anti-rat/anti-mouse antibody (Novus Biologicals, LLC, Littleton, CO). A horseradish peroxidase detection kit (Dako, Glostrup, DK) was used to assess immunoreactivity. Cell density and tumor localization were evaluated with hematoxylin and eosin staining. Sections were visualized and documented using bright field microscopy (Leica Microsystems, Inc., Buffalo Grove, IL, USA).
Statistical Analysis
Statistical analysis was performed with GraphPad Prism software (GraphPad Software Inc., La Jolla, CA). The significance (p value) of tumor-to-brain comparisons was determined using a paired t test. Data was considered significant when p values were less than 0.05.
Results
In Vivo Accumulation and Reversibility of [ 18 
F] VUIIS1008 in Healthy Tissues
Major organ accumulation and reversibility of [ 18 F]VUIIS1008 uptake was evaluated in healthy mice using dynamic PET scanning (n=2). In mice, the overall uptake of [ 18 F]VUIIS1008 was consistent with known TSPO densities inherent to healthy organs [18] and hepatic excretion. Thirty minutes after intravenous administration of [ 18 F]VUIIS1008, the greatest organ accumulation was observed in the myocardium, lung, renal tissue, and liver (Fig. 2a, b) . Intravenous administration of non-radioactive VUIIS1008 (10 mg/kg) at the scan mid-point resulted in rapid and significant displacement of [
18 F]VUIIS1008 from the myocardium and lung tissue and partial displacement from renal tissue (Fig. 2b, d , and e). Following displacement, slightly elevated radioactivity was observed in the liver, which appeared consistent with excretion ( Fig. 2b, d , and e). Similar displacement of [ 18 F]VUIIS1008 from the myocardium, lung, and renal tissue was achieved with an equivalent dosage of PBR06 (10 mg/kg), another well-documented TSPO ligand [23] (Fig. 2f) 18 F]VUIIS1008 were evaluated in C6 glioma-bearing rats. Accumulation (n=6, 90-min scans) and blocking (n =4, 60-min scans) were evaluated in dynamic PET studies (Fig. 3) . Prior to PET, C6 gliomas were localized with T 2 -weighted MRI (Fig. 3a) . Following administration, [ 18 F]VUIIS1008 exhibited accumulation in glioma tissue in preference to normal brain (Fig. 3b, c) . Relative to tumor, [ 18 F]VUIIS1008 exhibited modest accumulation in normal tissue. Mean TACs for the cohort of C6-bearing rats (n=6) illustrated rapid tracer delivery to both the tumor and normal brain, with each tissue exhibiting unique clearance profiles. Additionally, the tracer cleared rapidly from plasma (Fig. 3h) . In contrast to normal brain, [ 18 F]VUIIS1008 accumulated in tumors over time. Based upon the percentage of the injected dose per gram of tissue (%ID/g), a tumor-to-brain ratio of 3:1 was achieved by the conclusion of a 90-min scan (Fig. 3h) .
In blocking studies with non-radioactive VUIIS1008, [ 18 F]VUIIS1008 uptake was attenuated by approximately 50 % in the normal brain and tumor ( Fig. 3d, e; n=4) . A blocking dosage of 10 mg/kg of VUIIS1008 also led to significantly elevated plasma radioactivity compared with the unblocked scenario. In addition to lower tissue uptake, the blocking dose accelerated the clearance of [ 18 F]VUIIS1008 from the tumor and normal tissue (Fig. 3i) . To validate PET, imaging-matched rat brains were processed in the following histology analysis for postmortem staining and 18 F]VUIIS1008 prior to VUIIS1008 challenge (coronal view, a; sagittal view, c). Summation of the last 30 min of the dynamic acquisition following administration of 18 F-VUIIS1008 and following nonradioactive VUIIS1008 challenge (coronal view, b; sagittal viewd). TACs for the lung, heart, kidney, and liver; displacement with VUIIS1008 (10 mg/kg) (e). f TACs for the lung, heart, kidney, and liver; displacement with PBR06 (10 mg/kg). ROC retro-orbital cavity, %ID/cc percentage injected dose per cubic centimeter. %ID/cc for ROC at 60 min is 45.7 % in the image shown.
IHC, where close agreement between elevated TSPO levels ( Fig. 3f) and tumor tissue were observed by IHC (Fig. 3g) .
Compartmental Modeling
The pharmacokinetics of [ 18 F]VUIIS1008 uptake and clearance was modeled in the tumor and normal brain. As with other TSPO PET ligands evaluated in this setting [16] [17] [18] , [ 18 F]VUIIS1008 TACs for the tumor and normal brain more closely fit a two-tissue, four-rate-constant kinetic model compared to a one-tissue model, as determined by inspection and chi-squared values (Fig. 4) . In the two-tissue model, terms reflecting delivery and efflux from a non-binding compartment (K 1 , k 2 ) were not significantly different for [ 18 F]VUIIS1008 in the normal brain and tumor tissue. Delivery to the specific binding compartment (k 3 ) was also similar for the tumor and normal brain. However, a statistically significant difference was observed between k 4 values derived from the tumor and normal brain ( exhibited lower influx-to-efflux parameter ratios (K 1 /k 2 ) in the non-binding compartment for both the tumor (1.90 versus 6.87 ml/g) and brain (0.86 versus 3.62 ml/g) ( 18 F]DPA-714, yet V T ratios between the tumor and the normal brain were higher for [
18 F]VUIIS1008 (6.0 versus 4.4), which led to an apparent improved tumor-tonormal ratio with this tracer [16] . The %ID/cc ratio between the tumor and the normal brain at 90 min was slightly higher for [ 18 F]DPA-714 (4:1) than [ 18 F]VUIIS1008 (3:1) ( Table 2) . Blocking the uptake of [
18 F]VUIIS1008 with excess non-radioactive VUIIS1008 (10 mg/kg) led to significantly lower V T in both the tumor and the normal brain and a decreased tumor-binding potential (k 3 /k 4 ) ( Table 2) . 
Discussion
Our previous research has explored TSPO as a target for cancer molecular imaging [14] [15] [16] [17] 25] . Formerly referred to as peripheral benzodiazepine receptor (PBR), TSPO is an 18-kDa membrane protein typically localized to mitochondria. TSPO expression levels in the liver and brain are comparatively modest [5] . While frequently exploited as a target in neuroscience, elevated TSPO expression is also observed in cancers of the breast [12, 26] , prostate [11, 27] , oral cavity [28] , colon [14, 29, 30] , liver [31, 32] , and brain [33, 34] . In oncology, TSPO expression is reported to be associated with disease progression and diminished survival [28, 30, 35, 36] and is a hallmark of aggressive and potentially metastatic tumors [11] [12] [13] .
We have reported preclinical utilization of several PET probes for quantitative assessment of TSPO expression in glioma. These probes include N-[ [16] . In these PET imaging studies, tumors could be detected from the surrounding normal brain, and importantly, quantitative analyses of PET data agreed with ex vivo measures of TSPO levels [16, 17] . However, both of these agents demonstrated drawbacks, including sufficient tracer accumulation in the normal brain, which could potentially preclude detection of gliomas with modest TSPO expression, such as lower grade disease. Furthermore, both tracers demonstrated significant in vivo metabolism, which required a corrected plasma input function for quantitative analysis. While promising, these studies prompted the development of novel TSPO PET probes in our lab with improved properties for glioma imaging.
In this study, we quantitatively evaluated the in vivo performance of a novel TSPO PET ligand, [ 18 F]VUIIS1008. A seemingly minor structural alteration, substitution of the 5,7-methyl groups on the pyrazolopyrimidine ring of [ 18 F]DPA-714 with ethyl groups, yielded [ 18 F]VUIIS1008 (Fig. 1) , a probe with approximately 36-fold greater affinity for TSPO [18] . As shown in this study, this structural modification resulted in a number of intriguing and potentially improved properties for cancer imaging. Although not directly compared here, substitution of the 5,7-methyl with ethyl groups did not appear to confer a significant in vivo stability advantage, as revealed by the metabolism profiles for the new probe (Supplemental Table 2 ) and, when compared with [
18 F]DPA-714, were not remarkably different [16] .
Certain attributes of the new tracer and the attendant PET data that stem from its use warrant further exploration. For example, simple quantification of tracer uptake at a fixed time following injection (%ID/cc; 90 min), as would be routine in the clinical setting, actually yielded a slightly lower tumor-to-normal brain ratio for [ 18 F]VUIIS1008 (3:1) compared to [ 18 F]DPA-714 (4:1) [16] . Only with more sophisticated analysis of the dynamic PET acquisitions, which included pharmacokinetic modeling, arterial sampling, and metabolite correction, did we observe significantly greater tumorto-normal brain V T and BP ND ratios inherent to [ 18 F]VUIIS1008. While these techniques can obviously be incorporated into the research setting, they are not routine in clinical practice, highlighting a potential translational hurdle. Longer dynamic PET scans and compartmental analyses are also not routine in clinical practice. Further preclinical studies should evaluate the most appropriate acquisition and data analysis metrics that could be feasibly translated to human studies. 
